NEO Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Neogenomics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 15.3 USD 3.94%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast NEO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEO is 21.51 USD with a low forecast of 18.18 USD and a high forecast of 31.5 USD.

NEO Lowest Forecast

Wall Street Target

NEO Average Forecast

Wall Street Target

NEO Highest Forecast

Wall Street Target

19% Upside

41% Upside

106% Upside

The latest public price target was made on May 2, 2024 by Mark Massaro from BTIG , who expects NEO stock to rise by 37% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Mark Massaro BTIG	21 USD Upside 37%	3 days ago May 2, 2024	Neogenomics (NEO) PT Lowered to $21 at BTIG StreetInsider
Mason Carrico Stephens	18 USD Upside 18%	8 months ago Aug 21, 2023	Stephens Upgrades Neogenomics (NEO) to Overweight StreetInsider

Price Target	21 USD
Upside/Downside	37%

Price Target	18 USD
Upside/Downside	18%

Fortrea Holdings Inc

10% Upside

ST Pharm Co Ltd

14% Upside

GemPharmatech Co Ltd

83% Upside

Compugen Ltd

158% Upside

Fortrea Holdings Inc

10% Upside

ST Pharm Co Ltd

14% Upside

GemPharmatech Co Ltd

83% Upside

Compugen Ltd

158% Upside

Diaceutics PLC

73% Upside

SKAN Group AG

12% Upside

Revvity Inc

28% Upside

Tecan Group AG

23% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Neogenomics Inc's revenue is 25%. The projected CAGR for the next 3 years is 10%.

25%

10%

-1%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-25%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-64%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for NEO is 21.51 USD with a low forecast of 18.18 USD and a high forecast of 31.5 USD.

For the last 8 years the compound annual growth rate for Neogenomics Inc's revenue is 25%. The projected CAGR for the next 3 years is 10%.

Join more than 134,200+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.